Skip to main content

OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis B Candidate OLX703A

Written by Customer Service on . Posted in Public Companies.

Previous non-clinical pharmacology study demonstrated substantial reduction in serum markers of HBV

SUWON, Republic of Korea, Oct. 20, 2021 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company has selected Pharmaron, a leading contract research organization based in China, to conduct non-clinical toxicity studies to evaluate the safety of OLX703A, OliX’s investigational therapeutic for hepatitis B (HBV).

OLX703A utilizes GalNAc-asiRNA technology and is designed to inhibit all HBV transcripts and proteins, including hepatitis B surface antigen (HBsAg). It allows suppression of HBV replication and has been confirmed to be functional against all major HBV genotypes and subtypes.

Last June, OliX conducted a non-clinical pharmacology study of OLX703A and observed an approximately 100-fold reduction of key markers in serum associated with HBV, including s-antigen, e-antigen, and HBV DNA. According to the Company, these key results are comparable to the published preclinical data of competing therapeutics. Active pharmaceutical ingredient (API) production of OLX703A for preclinical and clinical studies is currently underway with LGC BioSearch Technologies.

“We are pleased to work with Pharmaron to advance non-clinical toxicity studies for OLX703A given their extensive research and development experience in China and the broader Asia region,” said Dong Ki Lee, Ph.D., founder and chief executive officer of OliX Pharmaceuticals. “We are encouraged by our progress in developing therapeutics for liver disease based on our GalNAc-asiRNA technology and look forward to advancing OLX703A into clinical trials as quickly as possible.”

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered the most efficient gene silencing technology. Utilizing this proprietary asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target diseases locally, such as hypertrophic scarring, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

Learn more: https://www.olixpharma.com/eng/

Media Contact:

Jon Yu
ICR Westwicke PR
Phone: +1.475.395.5375
jon.yu@westwicke.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.